BFC Planning’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-200
Closed -$26.5K – 3474
2026
Q2
$26.5K Buy
+200
New +$18K ﹤0.01% 1873

Other funds holding APGE

BFC Planning's APGE Position: Q3 2026 in Review

BFC Planning sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 200 shares — an estimated $26.5K sold.

BFC Planning first reported a position in APGE in Q2 2026 and held it in 1 quarter. The position peaked at $26.5K in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • BFC Planning reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • BFC Planning sold 200 Apogee Therapeutics shares in Q3 2026, an estimated $26.5K.
  • BFC Planning first reported a position in Apogee Therapeutics in Q2 2026 and held it in 1 quarter.
  • BFC Planning's Apogee Therapeutics position peaked at $26.5K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.